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First described in 1958 in Uganda, Burkitt lymphoma (BL) attracted interest worldwide following reports of its
uneven geographic distribution and rapidly fatal clinical course. Both suggested infectious etiology and curability.
Seminal discoveries followed in quick succession. Viral etiology – due to Epstein-Barr virus (EBV) – was confirmed.
Chromosomal translocations, involving cellular MYC, a protooncogene, were discovered, shown to be a hallmark of
BL, and central to the genetic basis of cancer. Cure of BL using combination chemotherapy was demonstrated.
Unfortunately, civil disturbance in Africa disrupted BL research and blunted its impact on education and oncology
care in Africa. Important questions went unanswered. The risk of BL due to malaria or EBV was not quantified.
Efforts to answer whether BL could be prevented – by preventing malaria or early EBV infection – were abandoned.
The mechanism of malaria in BL is unknown. In Africa, BL remains mostly fatal and diagnosis is still made clinically.
Unprecedented advances in molecular, genomics and proteomic technologies, promising to unlock mysteries of
cancers, have re-awakened interest in BL. With return of stability to Africa, the unanswered questions about BL are
re-attracting global interest. This interest now includes exploiting the knowledge gained about genetics,
proteomics, and bioinformatics to enable the development of targeted less toxic treatment for BL; and simpler
methods to diagnose BL with high accuracy and sensitivity. The articles in the Burkitt Lymphoma (BL): Beyond
Discoveries in Infectious Agents and Cancer highlight BL as priority. Authors explore etiology, pathology, pathogenesis
of BL, and whether knowledge gained in the studies of BL can catalyze sustainable cancer services in one of the
world’s poorest served regions.Burkitt lymphoma: beyond discoveries
Infectious Agents and Cancer is pleased to present a
thematic series entitled Burkitt Lymphoma (BL): Beyond
Discoveries. BL is an aggressive non-Hodgkin lymphoma
(NHL) [1] that was first described in African children
by Dennis Burkitt [2]. Within less than 10 years, Burkitt’s
report of an obscure tumor in Africa had a dramatic im-
pact on epidemiology, virology, immunology and on-
cology, spawning over 10,000 publications within a few
decades of it’s description in 1958 [3]. Originally consid-
ered peculiar to Africa, characterization of histochemical
and cytological properties of BL [1,4,5] led to recognition
of cases worldwide and realization that the discovery had
a universal relevance [6]. Notable geographic differences
in BL incidence were apparent and suggested etiology by a
vectored virus [7]. They also suggested an intuitive classifi-
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reproduction in any medium, provided the orat a high incidence and “sporadic BL” when occurring at
low incidence [7].
Study of BL led to a quick succession of seminal dis-
coveries. Epstein-Barr virus (EBV) was discovered in 1964
in tumor cells cultured from an African case examined by
electron microscopy [8]. Dramatic response to chemother-
apy and cure of BL was reported and replicated in trial
and error efforts [9,10]. Chromosomal translocations
involving light and heavy chain immunoglobulin genes
and MYC were discovered in BL tumors [11,12],
unlocking new ways to study tumor biology (Figure 1).
The study of mouse tumors with analogous translocations -
plasmacytomas -became an important resource to develop-
ing monoclonal antibodies. In 1969, after epidemiological
studies confirmed that EBV, the virus found in BL tumors,
was not transmitted by a vector [13], Dennis Burkitt pro-
posed recurrent infection with Plasmodium falciparum (Pf)
as co-factor in BL etiology [14]. Today, BL is considered a
model disease to understand the poly-microbial and the
genetic basis of cancer [15]. Specifically, a pathogenesis
model can be constructed (Figure 1), where the nodes of
risk comprise of exposures to infections that may increasetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 A cartoon showing a simple pathogenesis model of Burkitt lymphoma (BL) showing progression from a naïve B cell through
a necessary pre-malignant stage involving chromosomal translocation of MYC on chromosome 8 into the vicinity of promoter
elements of immunoglobulin genes on chromosome 14, 2, or 22 and progression of translocation-positive B cells to a clone of
malignant BL. The first stage is indicated by letter a and the second stage by letter b. The transit times for these stages are unknown, but
several assumptions are possible. First, exogenous exposures linked to high risk of BL, such as infection with malaria, Epstein-Barr virus, and
human immunodeficiency virus (HIV) – in the West – may act by increasing the absolute number (load) of translocation-positive B cells, which
would increase the number of initiated cells that can progress to BL and, hence, population incidence of BL. Second, the rate-limiting step of BL
is the apoptosis feedback loop in translocation-positive B cells. Thus, exposures that increase the survival, i.e., circumvent apoptosis feedback
loops in translocation-positive B cells until the abnormal cells develop capacity for self-perpetuation will increase the individual risk of BL.
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Figure 2 A schema showing studies of multi-factorial etiology
of Burkitt lymphoma (BL). Descriptive epidemiological studies
have demonstrated sex, age, and geography as risk factors.
Immunological and biomarker studies have demonstrated increased
risk related to infections that disrupt immunity, such as malaria,
human immunodeficiency virus, and use of solid organ
transplantation as risk factors. The genetic basis of BL remains largely
explored and represents the next frontier in BL research.
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exposures that confer longevity to translocation-positive B
cells by circumventing apoptosis feedback loops induced
by overexpression of c-MYC.
Many questions about BL remain unanswered. For
example, the definition of BL and its subtypes remains a
matter of debate [16]. Dennis Burkitt described a purely
clinical entity in Africa [2]. In 1969, a consensus conference
organized by the World Health Organization (WHO) in
Washington D.C. reviewed tumor tissues from patients
with clinical BL and reached a consensus definition that BL
was a distinct patho-biological entity characterized by
specific histological features or properties [17]. This patho-
logic definition has changed over the years as pathology
techniques have evolved. Refinements in histochemical
stains, morphological, cytogenetic, immunophenotypic and,
molecular techniques have led to description of classical
cases, variously referred to typical or classical BL, and
variant cases referred to as atypical BL or BL-like. The
pathology properties noted above are unrelated to the
intuitive clinico-epidemiological classification of BL as
endemic, sporadic, and immunodeficiency associated BL.
The infectious etiology of BL was recognized im-
mediately. Despite this, until the advent of the HIV epi-
demic and application of organ transplant technologies,
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vent organ rejection, no clear evidence linking immuno-
suppression in individuals to the risk of BL was adduced
[18]. Other provocative questions went unanswered.
These include why jaw tumors occur significantly more
commonly in males than females, particularly in pre-
pubescent children [19]. Because BL is endemic in
Africa, it has always been assumed that basal risk for
BL is higher in Blacks even in areas where BL is spor-
adic. However, data from the U.S., where many Blacks
live and BL is sporadic suggest that the risk of BL may
be lower in Blacks than Whites [20,21]. Why? Blacks in
the U.S. are more likely to be of a lower socioeconomic
status and therefore more likely to be exposed to EBV at a
younger age [22]. Assuming EBV conveys an independent
risk of BL risk, one would predict that the risk of BL
would be higher in Blacks than in Whites. Yet the oppos-
ite has been repeatedly observed, even in the setting of im-
munosuppression [23,24]. If EBV is relevant, then is early
exposure to EBV in the absence of malaria protective for
BL? If EBV is irrelevant, then do Blacks have a lower basal
genetic risk of BL? Or are there other local exposures in
Africa that are the culprit? Likewise, the higher risk of BL
in young males compared to females, observed in en-
demic, sporadic, and immunodeficiency BL is an unsolved
puzzle. Answers to these questions could provide new
clues about lymphoma biology. The endemicity of BL
maps quite well with holo-endemic malaria, in and outside
of Africa (example, Papua New Guinea). But if early acqui-
sition of EBV and malaria together increase risk for BL,
why is BL not endemic in other malarial regions, such as
in India and Burma? Are there differences in risk posed by
P. falciparum and P. vivax? Are differences in clinical pre-
sentations and EBV association of endemic and sporadic
BL indicative of truly different clinical entities? Are EBV
positive jaw tumors seen in ‘non endemic” settings like
Turkey [25] similar to disease in Africa?
The treatment approaches of BL in the West reflect
lessons learnt from trial and error efforts treating
endemic BL [26]. Today, treatment of BL is highly effect-
ive in the West and response and cure rates to present
day regimens are >90% [27]. In Africa, long-term cure
rates have remained low and have not moved beyond
rates of 25-30% described in early days [28]. While the
reasons for poor outcomes are due to limited resources
and capacity, it is also possible that many cases are
either not spotted or are diagnosed late and when
diagnosed and treated, they abandon treatment [29].
Would efforts to intensify case spotting, early diagnosis
and referral to treatment centers significantly affect
mortality in Africa [30]? Moreover, current BL treatment
is associated with life-threatening side effects, which
complicate its use in Africa where intensive-care services
are basic [31]. Would discovery of newer drugs, but withfewer side effects increase uptake and bring lifesaving
benefits to African children [32]. How could our under-
standing of the genetic and the poly-microbial basis of
BL be harnessed for treatment and prevention? How
EBV and malaria cause BL remains poorly understood
[3,33]. Clarifying the biological pathways exploited by
these infections to influence risk for BL (Figure 1) could
unlock ways to diagnose [34], treat and or prevent BL.
The outstanding of bottlenecks to BL research illustrated
by the cartoon include lack of methods to measure the
prevalence and load of c-MYC translocation-positive B
cells reliably and reproducibly in asymptomatic indi-
viduals [11,35]. Development of sensitive tests that can
be used in epidemiologic studies could clarify the role of
malaria, EBV, and other co-factors. Secondly, such tests
could open new avenues for investigation, including
cohort studies of children with a high load of c-MYC
translocation-positive B cells. While the brief review
indicates some understanding of epidemiological and
immunological risk factors of BL (Figure 2), our
understanding of the genetic basis of BL still remains
rudimentary. The interest in BL that is re-emerging is
timely because the unprecedented advances in molecu-
lar, genomics and proteomic technologies could unlock
the mysteries of BL and deliver on its promise as the Ro-
setta Stone of Cancer [36].
Through the articles in Burkitt Lymphoma (BL): Beyond
Discoveries, Infectious Agents and Cancer aims to highlight
BL as a priority, which allows unique opportunities for
scientists, policy makers, program managers in countries
where BL is endemic to collaborate. Their challenge will
be to answer to what extent the discoveries made about
BL will impact the life of a child with or at risk of BL in
Africa. Can knowledge gained in the studies of BL,
conducted both in African countries solely outside Africa,
be translated into affordable implementable programs that
introduce or catalyze sustainable cancer services in one of
the world’s poorest served regions [37]. Some of these
questions are not be new, but there are new toolboxes in
the present genomic era to answer new and old questions.
These issues and others, not explicitly touched, will be
discussed in the various papers collected in the thematic
issue introduced here.
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